Asthmatic

Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects

Condition:   AsthmaInterventions:   Drug: Fluticasone furoate (FF) Dry Powder Inhaler;   Drug: Fluticasone propionate (FP) Dry Powder Inhaler;   Drug: Budesonide (BUD) Turbuhaler;   Drug: Placebo (ELLIPTA or DISKUS)Sponsor:   GlaxoSmithKlineNot yet recruiting – verified December 2016 View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days

Pentoxifylline and its active metabolite lisofylline attenuate transforming growth factor ?1-induced asthmatic bronchial fibroblast-to-myofibroblast transition.

Pentoxifylline and its active metabolite lisofylline attenuate transforming growth factor ?1-induced asthmatic bronchial fibroblast-to-myofibroblast transition. Acta Biochim Pol. 2016 Jul 30; Authors: Wójcik-Pszczo?a K, Hi?cza K, Wnuk D, K?dzio?ka D, Koczurkiewicz P, Sanak M, Madeja Z, P?kala E, Michalik M…